<DOC>
	<DOCNO>NCT00432679</DOCNO>
	<brief_summary>This study design compare efficacy safety BRL49653C versus placebo concomitant use sulfonyl urea ( SU ) .</brief_summary>
	<brief_title>A Study Of BRL49653C For The Treatment Of Type 2 Diabetes ( Combination Therapy With Sulfonyl Urea ) -With Placebo Study</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Rosiglitazone</mesh_term>
	<criteria>Inclusion criterion : Patients type 2 diabetes mellitus manage SU candidate study . These candidate check clinical laboratory data , must adequate blood , liver kidney function . Exclusion criterion : Patient serious cardiovascular disease serious hepatic disease eligible .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>rosiglitazone</keyword>
	<keyword>Avandia</keyword>
	<keyword>type 2 diabetes mellitus</keyword>
	<keyword>diabetes</keyword>
</DOC>